4QG Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.15 |
| 52 Week High | NOK 0.23 |
| 52 Week Low | NOK 0.10 |
| Beta | 1.73 |
| 11 Month Change | 10.74% |
| 3 Month Change | 0.79% |
| 1 Year Change | -18.05% |
| 33 Year Change | -88.23% |
| 5 Year Change | n/a |
| Change since IPO | -89.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 40.5% | -1.1% | 1.1% |
| 1Y | -18.0% | -18.8% | 7.2% |
Return vs Industry: 4QG matched the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 4QG underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 4QG volatility | |
|---|---|
| 4QG Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4QG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4QG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.
PCI Biotech Holding ASA Fundamentals Summary
| 4QG fundamental statistics | |
|---|---|
| Market cap | €5.25m |
| Earnings (TTM) | -€1.36m |
| Revenue (TTM) | €513.11k |
10.2x
P/S Ratio-3.9x
P/E RatioIs 4QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4QG income statement (TTM) | |
|---|---|
| Revenue | NOK 6.00m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 6.00m |
| Other Expenses | NOK 21.91m |
| Earnings | -NOK 15.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -265.24% |
| Debt/Equity Ratio | 0% |
How did 4QG perform over the long term?
See historical performance and comparison